Asia Pacific Biosimulation Market Report and Forecast 2024-2032

The global biosimulation market size was valued at USD 3.5 billion in 2023, with Asia Pacific holding a significant market share. The market is driven by the rising advancement in biosimulation technologies. It is expected to grow at a CAGR of 16.90% during the forecast period of 2024-2032, with the values likely to attain USD 14.1 billion by 2032.

Key Takeaways

• The prevalence of at least one chronic disease among the adults and elderly population in India is estimated to be 41.73%. The rising burden of chronic disease fuels the need for effective drugs, thereby impacting market demand.
• In November 2023, Certara, Inc., introduced Simcyp™ Biopharmaceutics software which is designed to optimize the formulation and development of complex novel and generic small molecule medicines. The rising adoption of such technologically advanced biosimulation platforms in pharmaceutical and biotechnology companies is likely to elevate the Asia Pacific biosimulation market value.
• The market is positively influenced by increasing recognition of biosimulation technologies in improving clinical decisions and patient-specific therapies. In March 2024, a study on gastroesophageal cancer using the Cellworks Biosimulation Platform revealed superior overall survival (OS) and disease-free survival (DFS) predictions for the patients.

Asia Pacific Biosimulation Market Analysis

Biosimulation can be defined as a computational and mathematical modeling technique that is leveraged to simulate biological processes and systems. Biosimulation models can help predict the behavior of the drugs inside the human body, thereby reducing the time and cost associated with the drug development process. The rapid pharmaceutical expansion in the region is fuelling the demand for such simulation tools for accelerating drug development and is expected to significantly contribute to the Asia Pacific biosimulation market growth.

In Asia Pacific, healthcare demands are witnessing a surge due to an increasing prevalence of chronic diseases and the rising geriatric population in countries such as India and China. The prevalence of at least one chronic disease among the adults and elderly population in India is estimated to be 41.73%. This rising burden of chronic disease reflects the need to develop effective drugs faster. Since biosimulation can expedite the development of targeted therapy and personalized medicine, the market share is expected to grow in the forecast period.

One of the major Asia Pacific biosimulation market trends is the rise in launches of technologically advanced biosimulation software with enhanced capabilities and more accurate modeling. In November 2023, the global provider of biosimulation software and technology, Certara, Inc., introduced Simcyp™ Biopharmaceutics software which is designed to optimize the formulation and development of complex novel and generic small molecule medicines. It works by maximizing the safety and efficacy of therapies. The platform can help in predicting drug-drug interactions and drug performance in certain populations and can also replace costly clinical bioequivalence studies. The rising adoption of such biosimulation platforms in pharmaceutical and biotechnology companies in the region is likely to elevate the market value.

The Asia Pacific biosimulation market share is positively influenced by increasing recognition of biosimulation technologies in improving clinical decisions and patient-specific therapies. In March 2024, a study on gastroesophageal cancer using the Cellworks Biosimulation Platform (developed by Cellworks Group Inc.) revealed superior overall survival (OS) and disease-free survival (DFS) predictions for the patients. The study further highlighted the pivotal role of biosimulation in personalized therapy selection. Moreover, the increased application of biosimulation is expected to improve patient outcomes and lead to more cost-effective healthcare solutions. Consequently, this is likely to stimulate market demand in the coming years.

Asia Pacific Biosimulation Market Segmentation

Market Breakup by Product Type

• Services
• Software

Market Breakup by Application

• Drug Development
• Drug Discovery
• Other Applications

Market Breakup by Delivery Type

• Subscription Model
• Ownership Model

Market Breakup by End User

• Biotechnology and Pharmaceutical Companies
• Research Institutes
• Regulatory Authorities
• Contract Research Organizations

Market Breakup by Country

• Japan
• India
• ASEAN
• Australia
• Others

Asia Pacific Biosimulation Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

• LeadInvent Technologies
• Certara Corporation
• Simulations Plus, Inc.
• Dassault Systèmes BIOVIA Corp.
• Insilico Medicine, Inc.
• Physiomics plc
• BioDuro LLC
• Accelrys, Inc.
• Genedata AG
• Rhenovia Pharma
• Biomedical Simulation, Inc.

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

FAQs

What is the Asia Pacific biosimulation market forecast outlook for 2024-2032?
The Asia Pacific biosimulation market is expected to be driven by the rising demand for the global market, which is anticipated to grow at a CAGR of 16.90% during the forecast period of 2024-2032 and is likely to reach a market value of USD 14.1 billion by 2032.

What are the major factors aiding the Asia Pacific biosimulation market demand?
The rising advancement in biosimulation technologies is fuelling the demand for the market.

What are the major Asia Pacific biosimulation trends?
One of the significant trends in the market is the rise in launches of technologically advanced biosimulation software with enhanced capabilities. In November 2023, Certara, Inc., introduced Simcyp™ Biopharmaceutics software which is designed to optimize the formulation and development of complex novel and generic small molecule medicines.

What is the market segmentation based on the product type?
Based on the product type, the market is segmented into services and software.

What is the market breakup by delivery type?
By delivery type, the market is divided into the subscription model and ownership model.

What are the major end users of the market?
End users of the market are biotechnology and pharmaceutical companies, research institutes, regulatory authorities, and contract research organizations.

What are the applications of the market?
Major applications of biosimulation include drug development, and drug discovery, among other applications.

What is the market segmentation by countries?
The market segmentation by countries includes Japan, India, ASEAN, and Australia, among others.

Who are the key players involved in the Asia Pacific biosimulation market?
The key players in the market are LeadInvent Technologies, Certara Corporation, Simulations Plus, Inc., Dassault Systèmes BIOVIA Corp., Insilico Medicine, Inc., Physiomics plc, BioDuro LLC, Accelrys, Inc., Genedata AG, Rhenovia Pharma, and Biomedical Simulation, Inc.


This product will be delivered within 5-7 business days.